News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
708,447 Results
Type
Article (43049)
Company Profile (271)
Press Release (665127)
Multimedia
Podcasts (60)
Webinars (12)
Section
Business (205560)
Career Advice (2024)
Deals (35627)
Drug Delivery (97)
Drug Development (82107)
Employer Resources (172)
FDA (16387)
Job Trends (14993)
News (347987)
Policy (32799)
Tag
Academia (2645)
Accelerated approval (6)
Adcomms (22)
Allergies (86)
Alliances (49918)
ALS (105)
Alzheimer's disease (1470)
Antibody-drug conjugate (ADC) (132)
Approvals (16375)
Artificial intelligence (270)
Autoimmune disease (24)
Automation (17)
Bankruptcy (362)
Best Places to Work (11737)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (194)
Bladder cancer (79)
Brain cancer (28)
Breast cancer (293)
Cancer (2335)
Cardiovascular disease (179)
Career advice (1688)
Career pathing (30)
CAR-T (159)
Cell therapy (443)
Cervical cancer (20)
Clinical research (66810)
Collaboration (872)
Company closure (2)
Compensation (569)
Complete response letters (22)
COVID-19 (2612)
CRISPR (42)
C-suite (253)
Cystic fibrosis (102)
Data (2352)
Decentralized trials (2)
Denatured (19)
Depression (53)
Diabetes (277)
Diagnostics (6408)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (123)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (100)
Earnings (87331)
Editorial (42)
Employer branding (21)
Employer resources (146)
Events (113692)
Executive appointments (747)
FDA (17783)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (788)
Gene editing (111)
Generative AI (20)
Gene therapy (328)
GLP-1 (730)
Government (4464)
Grass and pollen (4)
Guidances (162)
Healthcare (18989)
Huntington's disease (26)
IgA nephropathy (28)
Immunology and inflammation (129)
Indications (29)
Infectious disease (2757)
Inflammatory bowel disease (145)
Inflation Reduction Act (8)
Influenza (53)
Intellectual property (99)
Interviews (316)
IPO (16609)
IRA (40)
Job creations (3669)
Job search strategy (1433)
Kidney cancer (10)
Labor market (43)
Layoffs (481)
Leadership (17)
Legal (7957)
Liver cancer (76)
Lung cancer (327)
Lymphoma (159)
Machine learning (9)
Management (58)
Manufacturing (331)
MASH (78)
Medical device (13595)
Medtech (13600)
Mergers & acquisitions (19593)
Metabolic disorders (714)
Multiple sclerosis (86)
NASH (16)
Neurodegenerative disease (115)
Neuropsychiatric disorders (31)
Neuroscience (2077)
NextGen: Class of 2025 (6588)
Non-profit (4532)
Now hiring (40)
Obesity (374)
Opinion (209)
Ovarian cancer (81)
Pain (98)
Pancreatic cancer (89)
Parkinson's disease (164)
Partnered (22)
Patents (246)
Patient recruitment (116)
Peanut (46)
People (57825)
Pharmaceutical (68)
Pharmacy benefit managers (20)
Phase I (20821)
Phase II (29436)
Phase III (21899)
Pipeline (1396)
Policy (150)
Postmarket research (2607)
Preclinical (8936)
Press Release (64)
Prostate cancer (110)
Psychedelics (31)
Radiopharmaceuticals (249)
Rare diseases (397)
Real estate (5951)
Recruiting (65)
Regulatory (22544)
Reports (47)
Research institute (2399)
Resumes & cover letters (350)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (78)
Series A (134)
Series B (95)
Service/supplier (11)
Sickle cell disease (52)
Special edition (19)
Spinal muscular atrophy (160)
Sponsored (29)
Startups (3632)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (50)
The Weekly (39)
Vaccines (706)
Venture capitalists (42)
Weight loss (240)
Women's health (36)
Worklife (16)
Date
Today (203)
Last 7 days (979)
Last 30 days (3216)
Last 365 days (32912)
2025 (12058)
2024 (35585)
2023 (40410)
2022 (51555)
2021 (56102)
2020 (54414)
2019 (46963)
2018 (35381)
2017 (32512)
2016 (31995)
2015 (38010)
2014 (31764)
2013 (26991)
2012 (29094)
2011 (29659)
2010 (27715)
Location
Africa (723)
Alabama (54)
Alaska (7)
Arizona (234)
Arkansas (13)
Asia (38384)
Australia (6338)
California (6454)
Canada (2073)
China (547)
Colorado (276)
Connecticut (283)
Delaware (158)
Europe (83566)
Florida (961)
Georgia (217)
Idaho (57)
Illinois (558)
India (25)
Indiana (324)
Iowa (11)
Japan (172)
Kansas (107)
Kentucky (25)
Louisiana (12)
Maine (62)
Maryland (924)
Massachusetts (4850)
Michigan (232)
Minnesota (406)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1810)
New Mexico (29)
New York (1822)
North Carolina (999)
North Dakota (8)
Northern California (2851)
Ohio (211)
Oklahoma (14)
Oregon (34)
Pennsylvania (1437)
Puerto Rico (13)
Rhode Island (33)
South America (1111)
South Carolina (26)
South Dakota (1)
Southern California (2422)
Tennessee (107)
Texas (954)
United States (24253)
Utah (190)
Virginia (152)
Washington D.C. (67)
Washington State (569)
West Virginia (3)
Wisconsin (57)
708,447 Results for "alzamend neuro inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alzamend Neuro Announces Reverse Stock Split
May 8, 2025
·
4 min read
Press Releases
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
May 8, 2025
·
5 min read
Press Releases
Alzamend Neuro to Present at the Sequire Investor Summit
January 15, 2025
·
3 min read
Policy
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
Alzamend Neuro, Inc. announced that the Nasdaq Hearings Panel granted Alzamend’s request to continue its listing on The Nasdaq Capital Market, subject to Alzamend demonstrating compliance, on or before September 23, 2024, with Listing Rule 5550, which requires stockholder equity of at least $2.5 million, and satisfying all applicable requirements for continued listing on Nasdaq.
May 22, 2024
·
3 min read
Press Releases
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
March 26, 2025
·
4 min read
Press Releases
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
March 19, 2025
·
5 min read
Press Releases
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
February 26, 2025
·
5 min read
Press Releases
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
March 4, 2025
·
5 min read
BioMidwest
Alzamend Neuro Announces Initial Closing of Private Placement
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder, announced that it closed upon the initial tranche of a private placement pursuant to the Securities Purchase Agreement with an institutional investor.
May 14, 2024
·
5 min read
Press Releases
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
March 11, 2025
·
6 min read
1 of 70,845
Next
